August 15, 2019
Buyers of the hypertension medication Exforge will have to pursue their pay-for-delay allegations against the drug's brand maker Novartis and generics company Par Pharmaceutical under a harder-to-prove legal standard, thanks to the U.S. Supreme Court's Actavis decision, a New York federal judge held Thursday.